fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Entacapone

All strengths: Limited Use, Reason for Use code 367 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 367 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Mint-Entacapone · DIN 02535939 · 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Entacapone · DIN 02535939 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-03-28 Health Canada: Marketed since 2024-02-21 · brand MINT-ENTACAPONE · ATC N04BX02 ENTACAPONE · form Tablet · route Oral · ingredients ENTACAPONE 200 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Entacapone: Formulary list price $0.40 per unit (the source does not state the unit; exact figure $0.4010). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02535939)

Source record
DIN 02535939: Mint-Entacapone Raw flags: sec12=Y, sec3=Y Item: 289200014; group id 538; item number 1456; lccId 00142; manufacturer id MIN Source form: Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4010; ministry $0.4010 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02535939 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102475
Interchangeable products
Comtan · DIN 02243763 · $0.4010 Sandoz Entacapone · DIN 02380005 · $0.4010 Teva-Entacapone · DIN 02375559 · $0.4010
Shortage status: anticipated shortage (last updated July 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535939
Shortage record checked October 6, 2026

Sandoz Entacapone · DIN 02380005 · 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Entacapone · DIN 02380005 Manufacturer: Sandoz Canada Inc.; listing date 2012-05-29 Health Canada: Marketed since 2012-03-30 · brand SANDOZ ENTACAPONE · ATC N04BX02 ENTACAPONE · form Tablet · route Oral · ingredients ENTACAPONE 200 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Entacapone: Formulary list price $0.40 per unit (the source does not state the unit; exact figure $0.4010). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02380005)

Source record
DIN 02380005: Sandoz Entacapone Raw flags: sec12=Y, sec3=Y Item: 289200014; group id 538; item number 1456; lccId 00142; manufacturer id SDZ Source form: Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4010; ministry $0.4010 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02380005 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86585
Interchangeable products
Comtan · DIN 02243763 · $0.4010 Mint-Entacapone · DIN 02535939 · $0.4010 Teva-Entacapone · DIN 02375559 · $0.4010
Shortage status: resolved shortage (ended June 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380005
Shortage record checked October 6, 2026

Teva-Entacapone · DIN 02375559 · 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Entacapone · DIN 02375559 Manufacturer: Teva Canada Limited; listing date 2012-05-29 Health Canada: Marketed since 2012-03-29 · brand TEVA-ENTACAPONE · ATC N04BX02 ENTACAPONE · form Tablet · route Oral · ingredients ENTACAPONE 200 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Entacapone: Formulary list price $0.40 per unit (the source does not state the unit; exact figure $0.4010). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02375559)

Source record
DIN 02375559: Teva-Entacapone Raw flags: sec12=Y, sec3=Y Item: 289200014; group id 538; item number 1456; lccId 00142; manufacturer id TEV Source form: Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4010; ministry $0.4010 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375559 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86097
Interchangeable products
Comtan · DIN 02243763 · $0.4010 Mint-Entacapone · DIN 02535939 · $0.4010 Sandoz Entacapone · DIN 02380005 · $0.4010
Shortage status: resolved shortage (ended July 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375559
Shortage record checked October 6, 2026

Comtan · DIN 02243763 · 200 mg · tablet

Limited Use, Reason for Use code 367 requiredDormant since September 8, 2023 · checked October 5, 2026 · What does dormant mean?
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Comtan · DIN 02243763 Manufacturer: Sandoz Canada Inc.; listing date 2003-04-16 Health Canada: Dormant since 2023-09-08 · brand COMTAN · ATC N04BX02 ENTACAPONE · form Tablet · route Oral · ingredients ENTACAPONE 200 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243763)

Source record
DIN 02243763: Comtan Raw flags: sec12=Y, sec3=Y Item: 289200014; group id 538; item number 1456; lccId 00142; manufacturer id SDZ Source form: Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.6837; ministry $0.4010 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243763 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67698
Interchangeable products
Mint-Entacapone · DIN 02535939 · $0.4010 Sandoz Entacapone · DIN 02380005 · $0.4010 Teva-Entacapone · DIN 02375559 · $0.4010
Shortage status: resolved shortage (ended March 10, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243763
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since September 8, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N04B): coverage varies; not interchangeable

  • Amantadine (Symmetrel): general benefit, not a benefit
  • Bromocriptine (Parlodel): general benefit, not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, limited Use, not a benefit
  • Pramipexole (Mirapex): general benefit, not a benefit
  • Ropinirole (ReQuip): general benefit, not a benefit

1 more in the class list below

Levodopa & carbidopa & entacapone

All strengths: Limited Use, Reason for Use code 367 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 367 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Stalevo · DIN 02305933 · 50 & 12.5 & 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Stalevo · DIN 02305933 Manufacturer: Sandoz Canada Inc.; listing date 2009-03-02 Health Canada: Marketed since 2020-07-24 · brand STALEVO · ATC N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR, N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 50 MG, CARBIDOPA 12.5 MG, ENTACAPONE 200 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stalevo: Formulary list price $1.75 per unit (the source does not state the unit; exact figure $1.7471). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02305933)

Source record
DIN 02305933: Stalevo Raw flags: sec12=Y, sec3=Y Item: 920000588; group id 933; item number 2226; lccId 00199; manufacturer id SDZ Source form: Tab; strength: 50 & 12.5 & 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.7471; ministry $1.7471 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02305933 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79150
Shortage status: resolved shortage (ended March 12, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02305933
Shortage record checked October 6, 2026

Stalevo · DIN 02337827 · 75 & 18.75 & 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Stalevo · DIN 02337827 Manufacturer: Sandoz Canada Inc.; listing date 2010-10-28 Health Canada: Marketed since 2020-07-24 · brand STALEVO · ATC N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR, N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 75 MG, ENTACAPONE 200 MG, CARBIDOPA 18.75 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stalevo: Formulary list price $1.75 per unit (the source does not state the unit; exact figure $1.7471). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337827)

Source record
DIN 02337827: Stalevo Raw flags: sec12=Y, sec3=Y Item: 920000615; group id 933; item number 2224; lccId 00199; manufacturer id SDZ Source form: Tab; strength: 75 & 18.75 & 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.7471; ministry $1.7471 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337827 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82347
Shortage status: resolved shortage (ended April 16, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337827
Shortage record checked October 6, 2026

Stalevo · DIN 02305941 · 100 & 25 & 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Stalevo · DIN 02305941 Manufacturer: Sandoz Canada Inc.; listing date 2009-03-02 Health Canada: Marketed since 2020-07-24 · brand STALEVO · ATC N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR, N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG, ENTACAPONE 200 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stalevo: Formulary list price $1.75 per unit (the source does not state the unit; exact figure $1.7471). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02305941)

Source record
DIN 02305941: Stalevo Raw flags: sec12=Y, sec3=Y Item: 920000589; group id 933; item number 2227; lccId 00199; manufacturer id SDZ Source form: Tab; strength: 100 & 25 & 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.7471; ministry $1.7471 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02305941 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79151
Shortage status: resolved shortage (ended July 8, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02305941
Shortage record checked October 6, 2026

Stalevo · DIN 02337835 · 125 & 31.25 & 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Stalevo · DIN 02337835 Manufacturer: Sandoz Canada Inc.; listing date 2010-10-28 Health Canada: Marketed since 2020-07-24 · brand STALEVO · ATC N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR, N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 125 MG, CARBIDOPA 31.25 MG, ENTACAPONE 200 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stalevo: Formulary list price $1.75 per unit (the source does not state the unit; exact figure $1.7471). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337835)

Source record
DIN 02337835: Stalevo Raw flags: sec12=Y, sec3=Y Item: 920000616; group id 933; item number 2225; lccId 00199; manufacturer id SDZ Source form: Tab; strength: 125 & 31.25 & 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.7471; ministry $1.7471 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337835 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82348
Shortage status: resolved shortage (ended March 12, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337835
Shortage record checked October 6, 2026

Stalevo · DIN 02305968 · 150 & 37.5 & 200 mg · tablet

Limited Use, Reason for Use code 367 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 367 (criteria below)
Ontario Limited Use criteria, code 367
Reason for Use code 367 For the treatment of patients with Parkinson's disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Stalevo · DIN 02305968 Manufacturer: Sandoz Canada Inc.; listing date 2009-03-02 Health Canada: Marketed since 2020-07-24 · brand STALEVO · ATC N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR, N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 37.5 MG, ENTACAPONE 200 MG, LEVODOPA 150 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Stalevo: Formulary list price $1.75 per unit (the source does not state the unit; exact figure $1.7471). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02305968)

Source record
DIN 02305968: Stalevo Raw flags: sec12=Y, sec3=Y Item: 920000590; group id 933; item number 2228; lccId 00199; manufacturer id SDZ Source form: Tab; strength: 150 & 37.5 & 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.7471; ministry $1.7471 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02305968 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79152
Shortage status: resolved shortage (ended July 29, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02305968
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N04B): coverage varies; not interchangeable

  • Amantadine (Symmetrel): general benefit, not a benefit
  • Bromocriptine (Parlodel): general benefit, not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, limited Use, not a benefit
  • Pramipexole (Mirapex): general benefit, not a benefit
  • Ropinirole (ReQuip): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

MEMANTINE HCL

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 38 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-ENTACAPONE (entacapone) is indicated as an adjunct to levodopa/carbidopa or levodopa/ benserazide preparations to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose “wearing-off” (see CLINICAL PHARMACOLOGY: Clinical Trials). Entacapone’s effectiveness has not been systematically evaluated in patients with idiopathic Parkinson’s Disease who do not experience end-of-dose “wearing-off”. 7 Since TEVA-ENTACAPONE is to be used in combination with a levodopa/DDC inhibitor, the complete prescribing information for levodopa/carbidopa and levodopa/benserazide are also applicable when TEVA-ENTACAPONE is added to the treatment regimen. https://pdf.hres.ca/dpd_pm/00028127.PDF PM date: November 3, 2014 Source product: TEVA-ENTACAPONE; DIN 02375559; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE STALEVO® (levodopa, carbidopa and entacapone) is indicated to treat patients with idiopathic Parkinson’s disease: • To substitute for immediate-release levodopa/carbidopa and entacapone previously administered as individual products. • To replace immediate-release levodopa/carbidopa therapy (without entacapone) when patients experience the signs and symptoms of end of dose "wearing off" (only recommended when patients are taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION). Geriatrics: No adjustment of STALEVO dosage is necessary in elderly patients. Pediatrics (< 18 years of age): Safety and effectiveness in pediatric patients have not been established. STALEVO is not indicated for use in children under 18 years of age. https://pdf.hres.ca/dpd_pm/00057237.PDF PM date: July 21, 2020 Source product: STALEVO; DIN 02305933; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)